Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRAP1 | Q12931 | 9/20 | 0.46 |
| ▸ | HSP90B1 | P14625 | 7/20 | 0.46 |
| ▸ | HSP90AA1 | P07900 | 5/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1054374 | 0.77 | TRAP1 (0.52) | TRAP1HSP90B1HSP90AA1 | |
| SCHEMBL27811496 | 0.75 | LMNA (0.30) | — | |
| SCHEMBL1080773 | 0.70 | ALDH1A1 (0.35) | — | |
| SCHEMBL12613677 | 0.70 | TLK2 (0.30) | — | |
| SCHEMBL1080775 | 0.70 | ALDH1A1 (0.35) | — | |
| SCHEMBL1080771 | 0.70 | ALDH1A1 (0.35) | — | |
| SCHEMBL1052264 | 0.66 | TRAP1 (0.73) | TRAP1HSP90B1HSP90AA1 | |
| SCHEMBL1059998 | 0.65 | TRAP1 (0.54) | TRAP1HSP90B1HSP90AA1 | |
| SCHEMBL1057826 | 0.65 | TRAP1 (0.59) | TRAP1HSP90B1HSP90AA1 | |
| SCHEMBL1060933 | 0.65 | HSP90AA1 (0.56) | TRAP1HSP90B1HSP90AA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110124634-A1 | BIOACTIVE COMPOUNDS FOR TREATMENT OF CANCER AND NEURODEGENERATIVE DISEASES | PONIARD PHARMACEUTICALS, INC. | 2011-05-26 | — | — | US | disclosed |
| US-20110124634-A1 | BIOACTIVE COMPOUNDS FOR TREATMENT OF CANCER AND NEURODEGENERATIVE DISEASES | PONIARD PHARMACEUTICALS, INC. | 2011-05-26 | — | — | US | disclosed |
| US-20110124634-A1 | BIOACTIVE COMPOUNDS FOR TREATMENT OF CANCER AND NEURODEGENERATIVE DISEASES | PONIARD PHARMACEUTICALS, INC. | 2011-05-26 | — | — | US | disclosed |
| EP-2273882-A1 | BIOACTIVE COMPOUNDS FOR TREATMENT OF CANCER AND NEURODEGENERATIVE DISEASES | Poniard Pharmaceuticals, Inc. (US) | 2011-01-19 | — | — | EP | disclosed |
| WO-2009139834-A1 | BIOACTIVE COMPOUNDS FOR TREATMENT OF CANCER AND NEURODEGENERATIVE DISEASES | PONIARD PHARMACEUTICALS, INC. (US) | 2009-11-19 | — | — | WO | disclosed |
| WO-2009139834-A1 | BIOACTIVE COMPOUNDS FOR TREATMENT OF CANCER AND NEURODEGENERATIVE DISEASES | PONIARD PHARMACEUTICALS, INC. (US) | 2009-11-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110124634-A1 | BIOACTIVE COMPOUNDS FOR TREATMENT OF CANCER AND NEURODEGENERATIVE DISEASES | PARK7, BDNF, BACE1 | TRAP1 443/4885HSP90B1 1036/4885HSP90AA1 1418/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.